Zota Health Care Limited has reported its audited financial results for the quarter and year ended March 31, 2026, alongside a detailed investor presentation. The company achieved a consolidated revenue of ₹53,865.75 lakhs in FY26, a growth of 83.86% compared to ₹29,297.46 lakhs in the previous year. While revenue surged, the company reported a net loss of ₹7,407.74 lakhs for the fiscal year, widening from ₹5,673.89 lakhs in FY25. The Board of Directors approved the audited standalone and consolidated financial results in a meeting on May 22, 2026.

Q4FY26 & FY26 Financial Highlights

For the quarter ended March 31, 2026, revenue from operations stood at ₹16,317.53 lakhs, while EBITDA was recorded at ₹1,191.17 lakhs. On a year-on-year basis, Q4 revenue grew from ₹973 million to ₹1.6 billion, while the net loss for Q4 widened to ₹145 million compared to a loss of ₹129 million in the same period last year. The Board recommended a final dividend of Re. 1/- per equity share of Rs. 10/- each for the financial year 2025-26, subject to shareholder approval.

The table below summarises the key financial metrics for Q4FY26 and the full year FY26:

Operational Expansion

Zota Health Care significantly expanded its Davaindia network during the fiscal year. The total number of stores reached 2,579 nationwide by the end of March 2026, comprising 1,656 COCO (Company Owned Company Operated) and 923 FOFO (Franchise Owned Franchise Operated) outlets. The company added 997 new stores during FY26, marking the highest store addition in the pharma retail segment in a single financial year. The yearly Gross Merchandise Value (GMV) for the network stood at ₹45,706 lakhs.

Strategic Developments

The company appointed Mr. Mahendra Singh Dhoni and Mr. Suniel Shetty as brand ambassadors for its Davaindia platform. Additionally, Zota Health Care launched a new retail format called "All Day Stores" (ADS) through its subsidiary, Everyday Herbal Beauty Care Limited (EHBCL). To reinforce its backward integration strategy, the company increased its stake in EHBCL to 87.78% by acquiring 1,18,00,000 equity shares via a rights issue for ₹19.47 crore. The Board also approved the acquisition of 39,794 equity shares of Davaindia Health Mart Limited, a wholly-owned subsidiary, for ₹20.19 crore.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE358U01012/b5e489f81fb74700.pdf

Zota Health Care Limited has voluntarily fixed an upper cap limit for the cumulative remuneration payable to its Promoter Directors. The company has established that the total remuneration, including all perquisites and allowances, shall not exceed ₹12.00 crores in aggregate for a single financial year. This decision is part of an initiative to adopt better corporate governance practices and to moderate managerial remuneration while ensuring better allocation of capital for the company's growth.

The resolution follows representations received from key members of the promoter and promoter group. The directors who proposed this measure include Mr. Ketankumar Chandulal Zota, Non-executive Chairman; Mr. Moxesh Ketanbhai Zota, Managing Director; and Whole-time Directors Mr. Himanshu Muktilal Zota, Mr. Kamlesh Rajanikant Zota, and Mr. Viren Manukant Zota.

Validity and Approvals

The fixed upper cap limit of ₹12.00 crores is valid until the end of the financial year 2030. The implementation of this remuneration structure is subject to necessary approvals whenever applicable. The company communicated this decision to the stock exchanges to ensure compliance with regulatory disclosure requirements.

Key Details of Remuneration Cap